Aravive, Inc. ARAV
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.95M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.45
- Beta
- 2.19
- Short ratio
- 0.91
- Inst. own
- 8.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 26, 2024
- 50-d avg
- 0.101746
- 200-d avg
- 0.591229
- 1y target
- 0.25
Key statistics
- Market cap
- 2.95M
- Enterprise value
- -3.16M
- Trailing P/E
- 0.00
- Forward P/E
- -0.45
- PEG ratio
- 0.00
- Price / sales
- 0.42
- Price / book
- 1.74
- EPS (TTM)
- -0.76
- Beta
- 2.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.99M
- Revenue growth
- -44.40%
- Free cash flow
- -38.20M
- Total cash
- 8.54M
- Total debt
- 2.43M
- Return on equity
- -475.98%
- Shares outstanding
- 73.56M
- Short % of float
- 2.94%
- 50-day average
- 0.101746
- 200-day average
- 0.591229
Analyst view
Consensus: hold
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate -0.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 3, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.24 | -0.10 | +0.14 | +58.33% |
| Aug 21, 2023 | Jun 1, 2023 | -0.30 | -0.12 | +0.18 | +60.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2023 | Cantor Fitzgerald | down | Overweight | Neutral |
| Aug 2, 2023 | William Blair | down | Outperform | Market Perform |
| Aug 2, 2023 | EF Hutton | down | Buy | Hold |
| Aug 2, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 2, 2023 | BTIG | down | Buy | Neutral |
| Jul 20, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Aravive, Inc.
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aravive.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ARAV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Purchase | Dec 1, 2019 | 0 |
| ESHELMAN FREDRIC N | Officer, Director and Beneficial Owner | Stock Award(Grant) | Oct 23, 2022 | 0 |
| GIACCIA AMATO | Director | Stock Award(Grant) | Oct 23, 2022 | 1,213,650 |
| HEMRAJANI REKHA | Chief Executive Officer | Stock Award(Grant) | Jan 8, 2020 | 57,000 |
| HO PETER TAI CHING | Director | Stock Award(Grant) | Oct 23, 2022 | 55,353 |
| HOWARD RUDY C. CPA | Chief Financial Officer | Stock Award(Grant) | Oct 23, 2022 | 10,870 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 6.50% | 4,784,214 | 6.03M | Jun 29, 2023 |
| Artal Group S.A. | 6.22% | 4,572,515 | 5.76M | Jun 29, 2023 |
| Baker Brothers Advisors, LLC | 4.43% | 3,261,224 | 4.11M | Jun 29, 2023 |
| Vanguard Group Inc | 2.15% | 1,583,473 | 2.00M | Jun 29, 2023 |
| New Leaf Venture Partners, L.L.C. | 1.29% | 946,423 | 1.19M | Jun 29, 2023 |
| Blackrock Inc. | 0.44% | 320,897 | 404.33K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.72% | 1,266,713 | 1.60M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.43% | 315,214 | 397.17K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.19% | 140,300 | 176.78K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.10% | 71,365 | 121.32K | May 30, 2023 |
| iShares Micro Cap ETF | 0.10% | 71,916 | 10.71K | Aug 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.06% | 41,978 | 71.36K | May 30, 2023 |